Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/9763
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | GEUSENS, Piet | - |
dc.date.accessioned | 2009-08-19T08:19:30Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | EXPERT OPINION ON BIOLOGICAL THERAPY, 9(5). p. 649-657 | - |
dc.identifier.issn | 1471-2598 | - |
dc.identifier.uri | http://hdl.handle.net/1942/9763 | - |
dc.description.abstract | Background: COX-inhibiting nitric oxide donators (CINODs) are a new class of drugs that combine the actions of the parent COX inhibitor with nitric oxide (NO), with the aim of reducing potential toxicity of the parent drug, while maintaining its analgesic and anti-inflammatory effects. AZD3582 (Naproxcinod (R)) is the first in the class of CINODs. Objective/methods: To review the effects of NO donation, CINODS in general and naproxen in osteoarthritis (OA), based on literature in PubMed. Results: in preclinical and human studies, this drug produced similar analgesic and anti-inflammatory effects to its parent naproxen, with improved gastrointestinal safety in OA patients. The results of recent clinical trials, which were designed to study effects on blood pressure, are expected shortly, after peer-review. Conclusions: As naproxen is considered the safest COX inhibitor choice from a cardiovascular perspective, AZD3582 has the potential to become a new drug treatment in patients with OA, in whom pain and function are not controlled by the use of analgesics. | - |
dc.language.iso | en | - |
dc.publisher | INFORMA HEALTHCARE | - |
dc.subject.other | CINODs; cycloogenase-inhibiting nitric oxide donators; Naproxcinod; osteoarthritis | - |
dc.title | Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD) | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 657 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 649 | - |
dc.identifier.volume | 9 | - |
local.format.pages | 9 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Geusens, Piet] Univ Hasselt, Biomed Res Inst, Maastricht, Belgium. | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.doi | 10.1517/14712590902926071 | - |
dc.identifier.isi | 000266227700010 | - |
item.fullcitation | GEUSENS, Piet (2009) Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). In: EXPERT OPINION ON BIOLOGICAL THERAPY, 9(5). p. 649-657. | - |
item.validation | ecoom 2010 | - |
item.contributor | GEUSENS, Piet | - |
item.fulltext | No Fulltext | - |
item.accessRights | Closed Access | - |
crisitem.journal.issn | 1471-2598 | - |
crisitem.journal.eissn | 1744-7682 | - |
Appears in Collections: | Research publications |
SCOPUSTM
Citations
23
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
22
checked on May 8, 2024
Page view(s)
64
checked on May 30, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.